Fight against COVID-19
Diagnostic antibody & antigen
Services
- Custom AAV Production
- Custom Adenovirus Production
- Custom Lentivirus Production
- Pre-made AAV Production
- Pre-made Adenovirus Production
- Pre-made Lentivirus Production
- AAV-LC3 Autophagy Flux Detection
- Ad-LC3 Autophagy Flux Detection
- Lv-LC3 Autophagy Flux Detection
- AAV Control Virus Production
- CRISPR/Cas9 AAV Production
- CRISPR/Cas9 Adenovirus Production
Supports
SOCAIL MEDIA
Landscape and collection of vaccine development against COVID-19 (2019 nCoV, SARS2 coronavirus)
| Platform | Type of candidate vaccine | Developer | Coronavirus target | Current stage of clinical evaluation/regulatory status- Coronavirus candidate | Same platform for non-Coronavirus candidates |
| DNA | DNA plasmid vaccine Electroporation device | Inovio Pharmaceuticals | COVID-19 | Pre-Clinical | Lassa, Nipah HIV,Filovirus HPV,Cancer indications Zika,Hepatitis B |
| DNA | DNA | Takis/Applied DNA Sciences/Evvivax | COVID-19 | Pre-Clinical | |
| DNA | DNA plasmid vaccine | Zydus Cadila | COVID-19 | Pre-Clinical | |
| Live Attenuated Virus | Deoptimized live attanuated vaccines | Codagenix/Serum Institute of India | COVID-19 | Pre-Clinical | HAV, InfA, ZIKV, FMD, SIV, RSV, DENV |
| Non- Replicating Viral Vector | MVA encoded VLP( virus-like vaccine) | GeoVax/BravoVax | COVID-19 | Pre-Clinical | LASV, EBOV, MARV, HIV |
| Non- Replicating Viral Vector | Ad26 (alone or with MVA boost) | Janssen Pharmaceutical Companies | COVID-19 | Pre-Clinical | Ebola, HIV, RSV |
| Non- Replicating Viral Vector | ChAdOx1 | University of Oxford | COVID-19 | Pre-Clinical | influenza, TB, Chikungunya, Zika, MenB, plague |
| Non- Replicating Viral Vector | adenovirus- based NasoVAX | Altimmune | COVID-19 | Pre-Clinical | influenza |
| Non- Replicating Viral Vector (Ad5) | Ad5 S (GREVAX™ platform) | Greffex | COVID-19 | Pre-Clinical | MERS |
| Non- Replicating Viral Vector (Ad5) | Oral Vaccine platform (Ad5) | Vaxart | COVID-19 | Pre-Clinical | InfA, CHIKV, LASV, NORV; EBOV, RVF, HBV, VEE |
| Non- Replicating Viral Vector (Ad5) | Viral-vectored based (Ad5) | CanSino Biologics(康希诺生物) | COVID-19 | Pre-Clinical | |
| Protein Subunit | Drosophila S2 insect cell expression system VLPs | ExpreS2ion | COVID-19 | Pre-Clinical | |
| Protein Subunit | S protein | WRAIR/USAMRIID | COVID-19 | Pre-Clinical | |
| Protein Subunit | S-Trimer | Clover Biopharmaceuticals Inc./GSK | COVID-19 | Pre-Clinical | HIV, REV Influenza |
| Protein Subunit | Peptide | Vaxil Bio | COVID-19 | Pre-Clinical | |
| Protein Subunit | Ii-Key peptide | Generex/EpiVax | COVID-19 | Pre-Clinical | Influenza, HIV, SARS- CoV |
| Protein Subunit | S protein | EpiVax/Univ. of Georgia | COVID-19 | Pre-Clinical | H7N9 |
| Protein Subunit | S protein (baculovirus production) | Sanofi Pasteur | COVID-19 | Pre-Clinical | Influenza, SARS-CoV |
| Protein Subunit | Full length S trimers/ nanoparticle + Matrix M | Novavax | COVID-19 | Pre-Clinical | RSV; CCHF, HPV, VZV, EBOV |
| Protein Subunit | S protein clamp | University of Queensland/GSK | COVID-19 | Pre-Clinical | Nipah, influenza, Ebola, Lassa |
| Protein Subunit | S1 or RBD protein | Baylor, New York Blood Center, Fudan University | COVID-19 | Pre-Clinical | SARS, MERS |
| Protein Subunit | Subunit protein, plant produced | iBio/CC-Pharming | COVID-19 | Pre-Clinical | |
| Replicating Viral Vector | Measles Vector | Zydus Cadila | COVID-19 | Pre-Clinical | |
| Replicating Viral Vector | Measles Vector | Institute Pasteur | COVID-19 | Pre-Clinical | West nile, chik, Eobla, Lassa, Zika |
| Replicating Viral Vector | Horsepox vector | Tonix Pharma/Southern Research | COVID-19 | Pre-Clinical | Smallpox, monkeypox |
| RNA | mRNA | China CDC/Tongji University/Stermina(斯微生物) | COVID-19 | Pre-Clinical | |
| RNA | mRNA | Moderna/NIAID | COVID-19 | Phase I | multiple candidates |
| RNA | mRNA | Arcturus/Duke-NUS | COVID-19 | Pre-Clinical | multiple candidates |
| RNA | saRNA | Imperial College London | COVID-19 | Pre-Clinical | EBOV; LASV, MARV, Inf (H7N9), RABV |
| RNA | mRNA | Curevac | COVID-19 | Pre-Clinical | RABV, LASV, YFV; MERS, InfA, ZIKV,DengV, NIPV |
| Unknown | Unknown | University of Pittsburgh | COVID-19 | Pre-Clinical | |
| Unknown | Unknown | University of Saskatchewan | COVID-19 | Pre-Clinical | |
| Unknown | Unknown | ImmunoPrecise | COVID-19 | Pre-Clinical | |
| Unknown | Unknown | MIGAL Galilee Research Institute | COVID-19 | Pre-Clinical | |
| Unknown | Unknown | Doherty Institute | COVID-19 | Pre-Clinical |
- GENEMEDI
- 6th Floor, Buiding No.2, Kangxin Road 3377, Shanghai, China
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
COVID-19
related
protocols,
data and
products